Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSIT: Transition from Methotrexate to Ustekinumab in Plaque Psoriasis
2008-008171-34Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ustekinumab in plaque psoriasis (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Treatment-emergent adverse events through Week 12. Started May 2009; status: completed.
02
Drugs
ustekinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2008-008171-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008171-34.